Terms: = Breast cancer AND FGFR3, CD333, 2261, ENSG00000068078, P22607, JTK4, ACH, HSFGFR3EX, CEK2 AND Treatment
28 results:
1. FGF2 drives osteosarcoma metastasis through activating FGFR1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
2. Chronic stress induces pulmonary epithelial cells to produce acetylcholine that remodels lung pre-metastatic niche of breast cancer by enhancing NETosis.
Pan J; Zhang L; Wang X; Li L; Yang C; Wang Z; Su K; Hu X; Zhang Y; Ren G; Jiang J; Li P; Huang J
J Exp Clin Cancer Res; 2023 Sep; 42(1):255. PubMed ID: 37773152
[TBL] [Abstract] [Full Text] [Related]
3. The prognostic and predictive values of differential expression of exosomal receptor tyrosine kinases and associated with the PI3K/AKT/mTOR signaling in breast cancer patients undergoing neoadjuvant chemotherapy.
Guney Eskiler G; Kazan N; Haciefendi A; Deveci Ozkan A; Ozdemir K; Ozen M; Kocer HB; Yilmaz F; Kaleli S; Sahin E; Bilir C
Clin Transl Oncol; 2023 Feb; 25(2):460-472. PubMed ID: 36181664
[TBL] [Abstract] [Full Text] [Related]
4. Multi-Gene Mutation Profiling by Targeted Next-Generation Sequencing in Premenopausal breast cancer.
Zografos E; Andrikopoulou A; Papatheodoridi AM; Kaparelou M; Bletsa G; Liontos M; Dimopoulos MA; Zagouri F
Genes (Basel); 2022 Jul; 13(8):. PubMed ID: 36011273
[TBL] [Abstract] [Full Text] [Related]
5. Hormone receptor binding, selectivity and cytotoxicity of steroid D-homo lactone loaded chitosan nanoparticles for the treatment of breast and prostate cancer cells.
Kuzminac IZ; Ćelić AS; Bekić SS; Kojić V; Savić MP; Ignjatović NL
Colloids Surf B Biointerfaces; 2022 Aug; 216():112597. PubMed ID: 35636320
[TBL] [Abstract] [Full Text] [Related]
6. Chlorpyrifos induces cell proliferation in MCF-7 and MDA-MB-231 cells, through cholinergic and Wnt/β-catenin signaling disruption, achE-R upregulation and oxidative stress generation after single and repeated treatment.
Moyano P; García JM; García J; Pelayo A; Muñoz-Calero P; Frejo MT; Anadon MJ; Naval MV; Flores A; Mirat VA; Del Pino J
Food Chem Toxicol; 2021 Jun; 152():112241. PubMed ID: 33930485
[TBL] [Abstract] [Full Text] [Related]
7. Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients.
Ross DS; Liu B; Schram AM; Razavi P; Lagana SM; Zhang Y; Scaltriti M; Bromberg JF; Ladanyi M; Hyman DM; Drilon A; Zehir A; Benayed R; Chandarlapaty S; Hechtman JF
Ann Oncol; 2020 Aug; 31(8):991-1000. PubMed ID: 32348852
[TBL] [Abstract] [Full Text] [Related]
8. Bladder cancer genomics.
Siracusano S; Rizzetto R; Porcaro AB
Urologia; 2020 May; 87(2):49-56. PubMed ID: 31942831
[TBL] [Abstract] [Full Text] [Related]
9. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung cancer.
Kichenadasse G; Miners JO; Mangoni AA; Rowland A; Hopkins AM; Sorich MJ
JAMA Oncol; 2020 Apr; 6(4):512-518. PubMed ID: 31876896
[TBL] [Abstract] [Full Text] [Related]
10. Analyses of fgfr3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines.
Kostopoulou ON; Holzhauser S; Lange BKA; Ohmayer A; Andonova T; Bersani C; Wickström M; Dalianis T
Int J Oncol; 2019 Dec; 55(6):1372-1384. PubMed ID: 31638167
[TBL] [Abstract] [Full Text] [Related]
11. Lichens exerts an anti-proliferative effect on human breast and lung cancer cells through induction of apoptosis.
Ozturk S; Erkisa M; Oran S; Ulukaya E; Celikler S; Ari F
Drug Chem Toxicol; 2021 May; 44(3):259-267. PubMed ID: 30835567
[TBL] [Abstract] [Full Text] [Related]
12. A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring
Voss MH; Hierro C; Heist RS; Cleary JM; Meric-Bernstam F; Tabernero J; Janku F; Gandhi L; Iafrate AJ; Borger DR; Ishii N; Hu Y; Kirpicheva Y; Nicolas-Metral V; Pokorska-Bocci A; Vaslin Chessex A; Zanna C; Flaherty KT; Baselga J
Clin Cancer Res; 2019 May; 25(9):2699-2707. PubMed ID: 30745300
[TBL] [Abstract] [Full Text] [Related]
13. Role of Muscarinic Acetylcholine Receptors in breast cancer: Design of Metronomic Chemotherapy.
Sales ME; Español AJ; Salem AR; Pulido PM; Sanchez Y; Sanchez F
Curr Clin Pharmacol; 2019; 14(2):91-100. PubMed ID: 30501602
[TBL] [Abstract] [Full Text] [Related]
14. Driver Fusions and Their Implications in the Development and treatment of Human cancers.
Gao Q; Liang WW; Foltz SM; Mutharasu G; Jayasinghe RG; Cao S; Liao WW; Reynolds SM; Wyczalkowski MA; Yao L; Yu L; Sun SQ; ; ; Chen K; Lazar AJ; Fields RC; Wendl MC; Van Tine BA; Vij R; Chen F; Nykter M; Shmulevich I; Ding L
Cell Rep; 2018 Apr; 23(1):227-238.e3. PubMed ID: 29617662
[TBL] [Abstract] [Full Text] [Related]
15. Clinical impact of extensive molecular profiling in advanced cancer patients.
Cousin S; Grellety T; Toulmonde M; Auzanneau C; Khalifa E; Laizet Y; Tran K; Le Moulec S; Floquet A; Garbay D; Robert J; Hostein I; Soubeyran I; Italiano A
J Hematol Oncol; 2017 Feb; 10(1):45. PubMed ID: 28179005
[TBL] [Abstract] [Full Text] [Related]
16. Therapeutics Targeting FGF Signaling Network in Human Diseases.
Katoh M
Trends Pharmacol Sci; 2016 Dec; 37(12):1081-1096. PubMed ID: 27992319
[TBL] [Abstract] [Full Text] [Related]
17. Norstictic Acid Inhibits breast cancer Cell Proliferation, Migration, Invasion, and In Vivo Invasive Growth Through Targeting C-Met.
Ebrahim HY; Elsayed HE; Mohyeldin MM; Akl MR; Bhattacharjee J; Egbert S; El Sayed KA
Phytother Res; 2016 Apr; 30(4):557-66. PubMed ID: 26744260
[TBL] [Abstract] [Full Text] [Related]
18. Complexity of FGFR signalling in metastatic urothelial cancer.
Rodriguez-Vida A; Saggese M; Hughes S; Rudman S; Chowdhury S; Smith NR; Lawrence P; Rooney C; Dougherty B; Landers D; Kilgour E; Arkenau HT
J Hematol Oncol; 2015 Oct; 8():119. PubMed ID: 26497743
[TBL] [Abstract] [Full Text] [Related]
19. IM-412 inhibits the invasion of human breast carcinoma cells by blocking FGFR-mediated signaling.
Jung SY; Yi JY; Kim MH; Song KH; Kang SM; Ahn J; Hwang SG; Nam KY; Song JY
Oncol Rep; 2015 Nov; 34(5):2731-7. PubMed ID: 26351897
[TBL] [Abstract] [Full Text] [Related]
20. Cholinergic receptors as target for cancer therapy in a systems medicine perspective.
Russo P; Del Bufalo A; Milic M; Salinaro G; Fini M; Cesario A
Curr Mol Med; 2014; 14(9):1126-38. PubMed ID: 25324001
[TBL] [Abstract] [Full Text] [Related]
[Next]
